Journal of Ophthalmology / 2019 / Article / Tab 3

Review Article

A Systematic Review and Meta-Analysis of Clinical Outcomes of Intravitreal Anti-VEGF Agent Treatment Immediately after Cataract Surgery for Patients with Diabetic Retinopathy

Table 3

Meta-analytic findings about postoperative macular thickness compared to the baseline.

No. of studiesMean difference (95% CI)I2 (%) for heterogeneity

MT after 1 week
 IVB for NPDR without DME
 IVR for NPDR without DME2 [16, 19]−11.69 (−19.56, −3.83)0.00400.80
 IVB for NPDR with DME
 IVR for NPDR with DME1 [18]−125.07 (−156.34, −93.80)0.00001Not applicable
Total3 [16, 18, 19]−45.95 (−91.49, −0.41)0.05960.00001

MT after 1 month
 IVB for NPDR without DME1 [12]−90 (−105.11, −74.89)0.00001Not applicable
 IVR for NPDR without DME3 [16, 19, 22]−16.56 (−26.10, −9.02)0.000180.34
 IVB for NPDR with DME2 [13, 21]−84.89 (−147.88, −21.91)0.008630.10
 IVR for NPDR with DME1 [18]−153.83 (−212.59, −95.07)0.00001Not applicable
Total9 [1113, 15, 16, 18, 19, 21, 22]−49.92 (−78.34, −21.51)0.0006930.00001

MT after 3 months
 IVB for NPDR without DME
 IVR for NPDR without DME3 [16, 19, 22]−25.64 (−32.54, −18.74)0.0000130.36
 IVB for NPDR with DME3 [13, 14, 21]−53.55 (−72.29, −34.80)0.0000100.57
 IVR for NPDR with DME1 [18]−108.80 (−170.64, −46.96)0.0006Not applicable
Total9 [11, 1316, 18, 19, 21, 22]−34.73 (−49.94, −19.51)0.00001580.01

MT after 6 months
 IVB for NPDR without DME1 [12]−24.00 (−34.50, −13.50)0.00001Not applicable
 IVR for NPDR without DME2 [16, 17]−24.77 (−43.24, −6.30)0.00900.88
 IVB for NPDR with DME1 [14]−109.84 (−174.48, −45.20)0.0009Not applicable
 IVR for NPDR with DME2 [18, 20]−90.25 (−127.24, −53.26)0.0000100.58
Total8 [11, 12, 1418, 20]−45.22 (−65.37, −25.07)0.00001620.01

IVB = intravitreal bevacizumab; IVR = intravitreal ranibizumab; NPDR = nonproliferative diabetic retinopathy; MT = macular thickness; DME = diabetic macular edema.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.